Protagonist Therapeutics Inc (NASDAQ:PTGX)

31.93
Delayed Data
As of 4:00pm ET
 +0.97 / +3.13%
Today’s Change
12.80
Today|||52-Week Range
50.54
+58.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Contact Information

Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Newark California 94560-1160
P:(510) 474-0170
Investor Relations:

Employees

Shareholders

Other institutional64.84%
Mutual fund holders37.04%
Individual stakeholders15.53%

Top Executives

Dinesh V. PatelPresident, Chief Executive Officer & Director
Donald A. KalkofenChief Financial Officer
Mark L. SmytheVice President-Technology
David Y. LiuChief Scientific Officer
Samuel R. SaksChief Medical Officer